| MOPEB03 | Safety and efficacy of 6-month rifampicin resistant TB regimens in people living with HIV: final analysis | Poster exhibition | Co-infections (including opportunistic infections) |
| MOPEB04 | Human Papillomavirus genotypes in adolescents and young adults living with HIV who received the quadrivalent HPV vaccine: The ZIMGARD cohort | Poster exhibition | Co-infections (including opportunistic infections) |
| MOPEB05 | Access to cervical cancer screening among women living with HIV in Malawi - analysis of Malawi population-based HIV impact assessment (MPHIA) 2020-21 and MPHIA 2015-16 surveys | Poster exhibition | Co-infections (including opportunistic infections) |
| MOPEB06 | Liver fibrosis regression measured by transient elastography in people living with HIV successfully treated for hepatitis C using direct acting antivirals | Poster exhibition | Co-infections (including opportunistic infections) |
| MOPEB07 | Early clinical experience using tecovirimat during the Mpox epidemic in Toronto suggests ongoing clinical equipoise for randomized trials | Poster exhibition | Co-infections (including opportunistic infections) |
| MOPEB08 | Characterization of mpox in people who live with HIV: a country-wide observational study | Poster exhibition | Co-infections (including opportunistic infections) |
| MOPEB09 | PEPFAR tuberculosis preventive treatment coverage and remaining gaps among people living with HIV | Poster exhibition | Co-infections (including opportunistic infections) |
| MOPEB10 | Performance of rifampicin resistant TB regimens used as standard-care in the TB-PRACTECAL clinical trial | Poster exhibition | Co-infections (including opportunistic infections) |
| MOPEB11 | Impact of HIV during standard first-line tuberculosis treatment on the risk of subsequent rifampicin-resistant TB in the Western Cape Province, South Africa | Poster exhibition | Co-infections (including opportunistic infections) |
| OAB0302 | HIV among mpox cases: clinical characteristics and outcomes in the WHO global surveillance 2022 | Oral abstract session with live Q&A | Co-infections (including opportunistic infections) |